Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

Condition:   End Stage Renal Disease on Dialysis Interventions:   Drug: Empagliflozin 25 mg vs Placebo;   Drug: Empagliflozin 10 MG Sponsors:   Yale University;   Boehringer Ingelheim Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials